23 results
DRS
MAIA
MAIA Biotechnology Inc
1 Jun 23
Draft registration statement
12:00am
of a product candidate for any or all targeted indications. In addition, drug-related side effects could affect patient recruitment or the ability
8-K
EX-99.1
MAIA
MAIA Biotechnology Inc
8 May 23
MAIA Biotechnology Reports First Quarter 2023 Financial Results and Provides Corporate Update
8:15am
the completed Part A safety lead-in of the THIO-101 Phase 2 go-to-market trial in advanced Non-Small Cell Lung Cancer (NSCLC) and commenced recruitment … Cell Lung Cancer (NSCLC) and commenced recruitment in Part B randomized efficacy/dose selection: Topline data from Part A demonstrated that MAIA’s
424B4
MAIA
MAIA Biotechnology Inc
25 Apr 23
Prospectus supplement with pricing info
7:45pm
, drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete a trial or result in potential product
8-K
EX-99.1
icw7 hcdeob0fs8dl
11 Apr 23
MAIA Biotechnology Reports Positive Topline Data from Part A Safety Lead-In of THIO-101 Phase 2 Trial for Non-Small Cell Lung Cancer
8:15am
8-K
4mt3yoqoetjfvn
11 Apr 23
MAIA Biotechnology Reports Positive Topline Data from Part A Safety Lead-In of THIO-101 Phase 2 Trial for Non-Small Cell Lung Cancer
8:15am
DRS
q0dqxdx9cidt9k1c
23 Dec 22
Draft registration statement
12:00am
424B4
80y9kp0j2o7kryi3ubf2
29 Jul 22
Prospectus supplement with pricing info
8:31am
S-1
EX-10.1
5gtp 2brfxwnuu
8 Apr 22
IPO registration
8:21pm